Aims: To perform a systematic literature review and meta-analysis of clinical risk factors for sudden cardiac death (SCD) in childhood hypertrophic cardiomyopathy. Methods: Medline and PubMed databases were searched for original articles published in English from 1963 through to December 2015 that included patients under 18 years of age with a primary or secondary end-point of either SCD or SCD-equivalent events (aborted cardiac arrest or appropriate implantable cardioverter-defibrillator discharge) or cardiovascular death (CVD). Results: Twenty-five studies (3394 patients) met the inclusion criteria. We identified four conventional major risk factors that were evaluated in at least four studies and that we found to be statistically associated with an increased risk of death in at least two studies: previous adverse cardiac event (pooled hazard ratio [HR] 5.4, 95% confidence interval [CI] 3.67-7.95, p < 0.001); non-sustained ventricular tachycardia (pooled HR 2.13, 95% CI 1.21-3.74, p ¼ 0.009); unexplained syncope (pooled HR 1.89, 95% CI 0.69-5.16, p ¼ 0.22); and extreme left ventricular hypertrophy (pooled HR 1.80, 95% CI 0.75-4.32, p ¼ 0.19). Left atrial diameter did not meet the major risk factor criteria; however, this is likely to be an additional significant risk factor. 'Minor' risk factors included a family history of SCD, gender, age, symptoms, electrocardiogram changes, abnormal blood pressure response to exercise and left ventricular outflow tract obstruction. Conclusions: A lack of well-designed, large, population-based studies in childhood hypertrophic cardiomyopathy means that the evidence base for individual risk factors is not robust. We have identified four clinical parameters that are likely to be associated with increased risk of SCD, SCD-equivalent events or CVD. Multi-centre prospective studies are needed in order to further determine the relevance of these factors in predicting SCD in childhood hypertrophic cardiomyopathy and to identify novel risk markers. Condensed abstract: A systematic review and meta-analysis of clinical risk factors predicting sudden cardiac death in childhood hypertrophic cardiomyopathy was performed, identifying four 'major' factors: previous adverse cardiac event; non-sustained ventricular tachycardia; syncope; and extreme left ventricular hypertrophy. Well-designed multi-centre studies are required in the future in order to confirm these findings.
Background
Hypertrophic cardiomyopathy (HCM) is defined as left ventricular hypertrophy (LVH) in the absence of loading conditions (hypertension, valve disease or congenital heart disease) that is sufEcient to cause the observed abnormality. 1 The true prevalence of HCM in childhood is unknown, but is estimated to be in the region of 2.9 per 100,000. [2] [3] [4] The aetiology of paediatric HCM is heterogeneous, and includes inborn errors of metabolism, malformation syndromes and neuromuscular disorders. However, most cases of HCM are caused by mutations in cardiac sarcomere protein genes, even in young children. 5, 6 The long-term prognosis of HCM in childhood is highly variable and depends to a large degree on the underlying aetiology. Estimates for sudden cardiac death (SCD) rates in childhood HCM vary widely, and recent epidemiological studies have reported rates of between 1% and 7.2% per year. [7] [8] [9] [10] [11] [12] One of the greatest challenges in managing young patients with HCM is the identification of individuals who are at highest risk of adverse events (AEs). Risk factors for SCD in adult HCM patients are well described and, recently, a novel risk model (HCM Risk-SCD) has been developed in order to improve the targeting of implantable cardioverter-defibrillators (ICDs). 14 However, this risk model is not validated for patients under 16 years of age, and the value of conventional 'adult' risk markers in children is uncertain. ICDs have been shown to be effective at aborting malignant arrhythmias in childhood HCM, 8, 13 but this is at the expense of a much higher rate of complications compared to adults. 15 This highlights the need for a greater understanding of the risk factors for SCD in childhood HCM in order to allow clinicians to robustly identify patients for primary prevention therapy. We therefore performed a systematic review and meta-analysis of the published literature in order to evaluate published risk factors in childhood HCM.
Methods

Study selection
The online MEDLINE database was searched using PubMed through the Medical Subject Headings (MeSH) terms ''((hypertrophic cardiomyopathy) AND (death OR sudden death OR cardiac death OR outcome OR prognosis OR risk factors) AND (children OR childhood OR young OR paediatric)). All searches were limited to: original articles written in English; patients aged <18 years; and those published from 1963 through to December 2015. This initial search strategy was supplemented by a manual search of the references for included papers and the most recent review articles.
Inclusion criteria
Studies reporting on a cohort of HCM patients with a primary or secondary end-point of either SCD, SCDequivalent events (aborted cardiac arrest or appropriate ICD discharge) or cardiovascular death (CVD) were included. Studies with an end-point of CVD secondary to heart failure alone were excluded.
We required that studies explored possible associations between clinical risk factors and survival; therefore, studies with no estimates of association were excluded (this included case reports and letters). We excluded those studies in which the patient cohorts were exclusively infants (aged <1 year) or had a mixed adult and paediatric population with <75% of the cohort under 18 years of age without separate analysis of paediatric data, or limited to rarer phenocopies such as Noonan syndrome or related disorders. As the study focused on clinical risk factors, studies exploring the use of genotyping or invasive markers to predict survival were excluded.
Data collection
The titles and abstracts of all studies identified by the search strategy were reviewed by two independent researchers (GN and NC) in order to determine eligibility. All eligible studies were read in full by the same two independent researchers. The following data were extracted from all included studies: patient characteristics (age and sex); study design; risk factor definition; length of follow-up and number of patients lost to follow-up; univariate and/or multivariable Cox regression analysis; event count data; and type of end-point (SCD, SCD-equivalent event or CVD). A quality assessment for each included study was performed in line with the Quality of Reporting of Meta-analyses (QUORUM) statement. 16 Survival analyses were not reported in all studies, and for these, count data were extracted in order to compute odds ratios (ORs) for SCD. For the major risk factors, pooled estimates of the HRs and/or ORs are reported. Average HRs/ORs were not calculated for minor risk factors because of the low number of studies.
Statistics
A random-effects meta-analysis was performed in order to combine the data from the included studies while accounting for between-study heterogeneity. The outcome of time to SCD (event of interest as described above) was addressed. SCD was also considered as a dichotomous outcome. In the first case, the results from each study's Cox proportional hazards regression analysis were combined using the generic inverse-variance (IV) method. Adjusted and unadjusted HRs were pooled together. When SCD was considered as a dichotomous outcome, the event counts and the numbers of those with and without the risk factor under investigation were extracted from the included studies in order to estimate the study OR. Pooled ORs were calculated using the Mantel-Haenszel (M-H) method. We report the pooled ORs and pooled HRs for each risk factor with a 95% confidence interval (CI) for each summary estimate. We also report I 2 , the percentage of variability in estimates due to heterogeneity between the studies. A significance level of 5% (p < 0.05) was used for analysis. The analysis was carried out using Review Manager (version 5.3). 37 Results Figure 1 summarises the search result. Briefly, the initial search identified 820 unique studies. By reading the titles and abstracts, 787 of these studies were excluded. The full-text versions were evaluated for the remaining 33 articles. This excluded a further eight articles. The reasons for exclusion are detailed in Figure 1 . Data were extracted from the remaining 25 articles that met the inclusion criteria (Table 1) . Of the included studies, the end-point measured was SCD in 10 studies (40%), all-cause CVD in 7 studies (28%) and both SCD and CVD in the remaining 8 studies (32%). In total, 23 clinical risk factors were studied. The definition of risk factors used in the included studies is detailed in Table 2 .
For the purpose of analysis, we divided the reported risk factors into two groups: probable/major risk factors (defined as being investigated as a potential risk factor in at least four studies and significantly associated with the end-point in at least two univariate or multivariable analyses); and possible/minor risk factors (defined as being significantly associated with the endpoint in one univariate or multivariable analysis study).
Major risk factors
Previous adverse cardiac event (aborted cardiac arrest or sustained ventricular tachycardia). Five studies 12, [17] [18] [19] [20] evaluated the prognostic value of a previous AE for SCD 12, [18] [19] [20] or CVD. 17 A significant association with SCD was shown in two univariate analyses (p < 0.0001, 19 p ¼ 0.004 20 ) and one multivariable analysis (p < 0.001 20 ) . Kamp et al. 18 described a small cohort of patients with previous ICD implantation in which a previous AE was not significant for SCD; however, this study was underpowered to detect a difference. Decker et al. 17 did not find an association with all CVDs; however, SCD was not analysed separately. The HR was 5.4 (95% CI 3.67-7.95, p < 0.001, I
2 ¼ 0%) (Figure 2(a) Figure 1 . Identification of studies included in the meta-analysis of risk factors for sudden cardiac death in paediatric hypertrophic cardiomyopathy. 5.06 (95% CI 2.11-12.17, p < 0.001, I 2 ¼ 0%) (Figure  2(b) ).
Syncope. Syncope was investigated as a potential risk factor for SCD in seven studies 10, 12, 15, [18] [19] [20] [21] and for CVD in one study. 17 Three of the identified studies reported a significant relationship between unexplained syncope/pre-syncope and SCD. 10, 19, 21 No significant association was seen between syncope and CVD. 17 The HR was 1.89 (95% CI 0.69-5.16, p ¼ 0.22, I
2 ¼ 46%) (Figure 3(a) ). The OR estimate for syncope was 2.64 (95% CI 1.21-5.79, p ¼ 0.02, I
2 ¼ 40%) (Figure 3(b) ). Peak gradient >15 mmHg [17, 22, 28] or >20 mmHg [12] or >30 mmHg [20, 31] by Doppler echocardiography in resting conditions Left atrial enlargement Maximum anteroposterior linear diameter z-score >2 measured at end-systole from the parasternal long-axis view [20] or left atrial-to-aortic root ratio !1.5 [24] Abnormal blood pressure response to exercise
Failure to increase systolic blood pressure by more than 20 mmHg from rest to peak exercise [17, 20] or a fall greater than 20 mmHg from peak pressure [17, 19, 20] 12, 15, 19, 20 or CVD. 17, 22 Two found a significant relationship between NSVT and SCD, 12, 15 with a further study reporting non-significance of NSVT, but significance for inducible VT during an electrophysiology study. 19 No studies reported a significant association between NSVT and CVD. 17, 22 The pooled HR was 2.13 (95% CI 1.21-3.74, p ¼ 0.009, I
2 ¼ 19%) (Figure 4(a) ). The pooled OR estimate for NSVT was 2.05 (95% CI 0.98-4.28, p ¼ 0.06, I
2 ¼ 11%) (Figure 4(b) ).
Left ventricular hypertrophy. LVH was the mostly frequently assessed risk marker; 12, 15, [17] [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] however, the measurement of LVH was highly variable. The most common measure of LVH was interventricular septal thickness, 12, 19, 20, [22] [23] [24] [25] [26] [27] for which two studies reported a significant association with SCD, 19, 26 and a further study found a correlation with CVD. 22 Six studies evaluated the predictive value of LV posterior wall thickness (LPWT), 20, 22, 23, 25, 27, 28 of which four showed a significant correlation between increasing LPWT and all-cause CVD 22, 23, 27, 28 and one study showed an association with SCD. 23 A LV wall thickness/cavity ratio > 0.3 was found to be significantly associated with CVD in the two studies reporting this measurement. 20, 26 No studies analysed its relationship with SCD. Finally, extreme LVH (as defined in Table 2) was evaluated in five studies 15, 17, 18, 20, 22 and found to be statistically associated with SCD in a third of studies using this outcome measure 15 and both studies looking at CVD. 17, 22 Another study showed increased risk of SCD with increasing LV wall thickness. 25 The HR for extreme LVH was 1.80 (95% CI 0.75-4.32, p ¼ 0.19, I
2 ¼ 21%) ( Figure 5(a) ). The OR estimate for extreme LVH was 1.70 (95% CI 0.85-3.40, p ¼ 0.13, I 2 ¼ 31%) ( Figure 5(b) ).
Minor risk factors
Family history of SCD. A family history of SCD was evaluated as a risk factor in seven studies. 12, [17] [18] [19] [20] 22, 27 Only one study reported a statistically significant association with SCD (HR 10.6, 95% CI 1.2-90.2, p ¼ 0.03). 18 Gender. Gender was investigated as a predictive factor for death in five studies. 18, 22, 23, 26, 27 The majority did not demonstrate a significant relationship, However, Lipshultz et al. 27 reported an increased risk of CVD in female patients (HR 2.4, 95% CI: 1.09-5.17, p ¼ 0.03).
Age. Age at presentation or diagnosis was investigated as a potential risk factor for death in 11 studies. 7, 11, 12, 19, 20, [22] [23] [24] [26] [27] [28] Presentation in infancy (<1 year of age) was consistently associated with an increased risk of CVD, likely secondary to congestive cardiac failure; 7, 22, 28 however, outside infancy, the majority of studies found no association between age and the risk of death. 12,20,22-24,27 Ö stman-Smith et al. reported an increased risk of SCD if the patient was younger at presentation. 26 In contrast, one study reported an increased risk of CVD in children presenting above 13 years of age, 19 and another if presenting between the ages of 9 and 14 years. Symptoms. Eight studies compared the risk of death in symptomatic and asymptomatic patients; 12, 17, 20, 21, 24, [26] [27] [28] however, the definition of symptomatic patients was highly variable. The presence of symptoms of congestive cardiac failure at presentation was significant in predicting an increased risk of CVD in three out of four studies with this end-point. 20, 21, 27 One study reported that other symptoms (including chest pain and palpitations) were also significantly associated with increased risk of CVD. 26 Only three studies assessed symptoms as risk factors for SCD, 12, 24, 26 of which only one found a significant association with SCD (HR 1.7, 95% CI 0.80-3.6, p ¼ 0.17). 24 However, this was a composite measure including syncope, previous AEs, chest pain, tachycardia and dizziness, and therefore may not be an independent risk factor. ECG changes. Five studies 12, 20, 26, 29, 30 that assessed the prognostic value of ECG changes were identified. QTc dispersion was analysed in two studies and found to be associated with SCD in both (HR 3.2, 95% CI 1.5-6.6, p ¼ 0.0042 20 ; relative risk (RR) 1.61, 95% CI 1.24-2.08, p ¼ 0. 0003 12 ). Other ECG parameters included R wave and S wave (RS) sum, which was analysed in one study and found to be significantly associated with SCD (HR 8.4 95% CI 2.2-33.2, p ¼ 0.0012), 26 and heart rate variability, which correlated with SCD in two studies; 29, 30 however, this only reached statistical significance in one study. 29 Abnormal blood pressure response to exercise. Blood pressure response to exercise was evaluated as a potential risk factor in four studies [17] [18] [19] [20] ; however, an abnormal blood pressure response to exercise (ABPE), as defined in Table 2 , was not found to be significantly associated with SCD. One study reported a significant relationship between ABPE and cardiovascular death (HR 9.6, 95% CI 1.0-93.1, p 0.03).
17
LV outflow tract obstruction. LV outflow tract obstruction (LVOTO) was assessed as a potential risk factor for SCD in two studies and CVD in four studies. 12, 17, 20, 22, 28, 31 A significant association with CVD was reported in one study (p ¼ 0.04). 22 Zio´lkowska et al. 20 reported a higher risk of SCD with increasing LVOTO gradient (p ¼ 0.04); however, whilst in the adult literature a gradient above 30 mmHg is predictive for SCD, a gradient above 30 mmHg was not predictive for SCD in this study.
Left atrial size. Left atrial (LA) size was investigated as a risk factor for SCD in three studies 20, 24, 25 and CVD in two studies. 20, 24 Increased LA size was significantly correlated with SCD in two studies (HR 3.125, 95% CI 1.45-6.74, p ¼ 0.001; 20 HR 3.4, 95% CI 1.1-11.2, p ¼ 0.049 24 ). Therefore, although LA size does not meet the criteria for classification as a major risk factor, it is likely to be a significant predictor for SCD.
Restrictive physiology. Three studies 20, 24, 25 analysed the predictive value of echocardiographic markers of restrictive physiology for SCD. The measurement of restrictive physiology varied and included: septal E/ E', 24,25 mitral inflow Doppler E/A ratio 20, 24 and LA enlargement without evidence of LV dilatation. 24 McMahon et al. 25 reported that early transmitral LV filling velocity (E)/septal E/A ratio predicted the risk of SCD (HR 6, p < 0.001), and Maskatia et al. 24 reported echocardiographic findings associated with restrictive physiology to be associated with a 3.8-fold increase in the risk of SCD (HR 3.8, p ¼ 0.302).
Strain. Strain as assessed by echocardiography was investigated as a risk factor for SCD in only one study, which reported a significant association of reduced global strain and increased risk of SCD (OR 1.13, 95% CI 1.00-1.27), but a non-significant relationship between SCD and longitudinal or radial strain. 32 24-hour blood pressure monitoring. Abnormal 24-hour ambulatory blood pressure monitoring was investigated as a risk factor for SCD in a single study, in which a significant association was shown between an abnormal blood pressure ratio (lower systolic blood pressure in the morning) and risk of SCD. 30 Late Gadolinium Enhancement on Cardiac Magnetic Resonance (CMR) imaging. 3 studies 38, 39, 40 were identified that looked at the predictive value of late gadolinium enhancement on CMR as a risk factor for SCD in childhood HCM. They reported an increased incidence of LGE in patients with adverse outcomes, however this did not reach statistical significance. In contrast the presence of LGE was statistically associated with increased LV wall thickness/mass.
Discussion
Risk factors for SCD in adult HCM patients are well described, and current European and American guidelines describe validated risk stratification algorithms for primary prevention. The American College of Cardiology Foundation/American Heart Association currently recommends that ICD implantation is reasonable if one major risk factor (family history of SCD, LV wall thickness >30 mm or unexplained syncope) is present and could be considered if two or more other risk factors are present. 34 In comparison, the European Society of Cardiology (ESC) has endorsed the use of a new SCD risk prediction model (HCM Risk-SCD) 14 that provides an individualised estimate for 5-year SCD risk by utilising predictor variables associated with multivariable analyses. However, these algorithms have not been validated in children and younger teenagers.
This study is, to our knowledge, the first systematic review of potential risk factors for SCD in childhood HCM. Although a large number of potential risk factors for SCD in childhood HCM have been reported in the literature over the past 30 years, the lack of consistent definitions and well-designed, large, population-based studies means that the evidence for individual risk factors is not robust.
Within both current European and American guidelines for the management of adults with HCM, short sections on the risk of SCD in childhood HCM 34, 35 recommend the use of four major risk factors to predict SCD: maximum LV wall thickness >30 mm or z-score >6; unexplained syncope; NSVT; and family history of SCD. ICD implantation is recommended for the primary prevention of SCD for those with two or more major risk factors. 8, 15, 17, 26, 35, 36 The present systematic review supports the inclusion of unexplained syncope and NSVT as likely major risk factors for SCD in paediatric HCM. The measurement and definition of LVH varied between studies; however, severe LVH was found to be associated with SCD in several studies, although pooled ORs/HRs were not significant at the 5% significance level. Interestingly, only one study showed a significantly increased risk of death with a LV wall thickness >30 mm/z-score >6, which is the definition that is endorsed by the ESC guidelines. The most clinically important measure of LVH and the appropriate cut off for measuring increased risk in paediatric HCM needs further investigation.
A family history of SCD was not classified as a major risk factor for paediatric HCM in our analysis, as only one paper reported a statistical relationship with sudden death. The ESC recommendations for the use of family history in children was based on a study 36 that was excluded from our review because less than 75% of patients were below 18 years of age in the cohort. There is significant evidence supporting a family history of SCD as a risk factor in adult HCM; however, there is currently a lack of data to support its role in paediatric HCM. Possible explanations for this observation may include a higher prevalence of de novo mutations in paediatric HCM, a small proportion of sarcomeric-positive patients and insufficient reporting of family history in the included studies. This needs further evaluation in future large-scale paediatric cohort studies.
In adults, evidence supports additional risk factors such as LA diameter, LVOTO or an ABPE, which can modify an individual's risk. Our data suggest that, in addition to the four 'major' risk factors described, other clinical variables are also likely to be useful for risk stratification in childhood. These additional risk factors may be the same in adulthood and childhood, such as LA size, which was significantly associated with SCD in two out of three studies. However, other variables such as LVOTO and an ABPE may not be as important in childhood compared to adulthood. Further studies are required in order to explore the potential association between these risk factors and risk of SCD in childhood HCM.
The validated SCD risk prediction model (HCM Risk-SCD) 14 described above, which provides an individualised estimate for 5-year SCD risk, is not validated for patients under 16 years of age. Additionally, although it is validated for patients aged 16-18 years, this group of patients constituted a small proportion of the cohort (n ¼ 82/3675, 2%), and therefore this group of patients requires further evaluation. This systematic review has provided evidence that, whilst some of the validated adult risk factors may be applicable to risk stratification in childhood HCM, such as LVH or syncope, others, such as ABPE, may be less relevant. The results of this systematic review suggest that further research is needed in order to develop a validated paediatric-specific risk prediction model for SCD in HCM.
The number of studies included in this meta-analysis is small, and of these, all but one was a retrospective cohort study. It is therefore limited by the intrinsic problems of retrospective studies, including missing and incomplete information. Childhood HCM is a rare disease and many of the included studies were small; all but three of the studies had fewer than 150 participants. Furthermore, the patient populations were heterogeneous, making comparisons between groups challenging. Adverse outcomes in this population are rare and outcomes are highly variable depending on the underlying aetiology, necessitating long follow-up periods in order to identify prognostic risk factors. Many of the included studies had low event counts, which is likely to have reduced their power to detect differences between groups. Additionally, as the patients in the included studies were often recruited from a small number of highly specialised tertiary services, which care for highly symptomatic individuals, it is possible that this patient group may have more severe disease and that duplication of patient data may have occurred in different studies. Collectively, these limitations mean that the applicability of the results of this study to individual patients and the wider HCM population is difficult to determine.
Finally, comparison between studies was complicated by differences in the study design, definitions of individual risk factors (including different z-score calculators) and study end-points. Diverse definitions were a particular problem for studies investigating the predictive role of 'symptoms' and 'LVH' for SCD. The use of 'appropriate ICD therapy' as a surrogate marker for SCD, although well established in both adult and paediatric studies, is a possible source of error, as it does not account for inappropriate ICD therapy, which has been reported to be more common in the paediatric population. Pooled estimates for average HRs and ORs were calculated; however, the precision of the estimates reported in the included studies is low,
